Pharmacokinetics of rifampicin in adult TB patients and healthy volunteers: a systematic review and meta-analysis

High-dose rifampicin, moxifloxacin, and SQ109 for treating tuberculosis: a multi-arm, multi-stage randomised controlled trial

(2017) Martin J Boeree et al.   LANCET INFECTIOUS DISEASES

Effect of Obesity on the Population Pharmacokinetics of Fluconazole in Critically Ill Patients

(2016) Abdulaziz S. Alobaid et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

A simultaneous population pharmacokinetic analysis of rifampicin in Malawian adults and children

(2016) Alessandro Schipani et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring

(2016) Roger K. Verbeeck et al.   EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY

Pharmacokinetics and safety/tolerability of higher oral and intravenous doses of rifampicin in adult tuberculous meningitis patients

(2016) Vycke Yunivita et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Pharmacokinetics of thrice-weekly rifampicin, isoniazid and pyrazinamide in adult tuberculosis patients in India

(2016) A. K. Hemanth Kumar et al.   INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE

Therapeutic Drug Monitoring in the Treatment of Active Tuberculosis

(2016) Aylin Babalik et al.   Canadian Respiratory Journal

A Dose-Ranging Trial to Optimize the Dose of Rifampin in the Treatment of Tuberculosis

(2015) Martin J. Boeree et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Understanding PK/PD

(2015) Jason A. Roberts et al.   INTENSIVE CARE MEDICINE

Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range

(2015) Xiang Wan et al.   BMC Medical Research Methodology

Conducting Meta-Analyses inRwith themetaforPackage

(2015) Wolfgang Viechtbauer   Journal of Statistical Software

Impact of Nonlinear Interactions of Pharmacokinetics and MICs on Sputum Bacillary Kill Rates as a Marker of Sterilizing Effect in Tuberculosis

(2014) Emmanuel Chigutsa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Therapeutic Drug Monitoring in the Treatment of Tuberculosis: An Update

(2014) Abdullah Alsultan et al.   DRUGS

Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

(2014) Jason A Roberts et al.   LANCET INFECTIOUS DISEASES

Optimization of the Rifampin Dosage to Improve the Therapeutic Efficacy in Tuberculosis Treatment Using a Murine Model

(2013) Jurriaan E. M. de Steenwinkel et al.   AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE

Serum Drug Concentrations Predictive of Pulmonary Tuberculosis Outcomes

(2013) J. G. Pasipanodya et al.   JOURNAL OF INFECTIOUS DISEASES

Advances in the development of new tuberculosis drugs and treatment regimens

(2013) Alimuddin Zumla et al.   NATURE REVIEWS DRUG DISCOVERY

Why Do We Use 600 mg of Rifampicin in Tuberculosis Treatment?

(2011) J. van Ingen et al.   CLINICAL INFECTIOUS DISEASES

Therapeutic drug monitoring in the treatment of tuberculosis patients

(2011) Cecile Magis-Escurra et al.   PULMONARY PHARMACOLOGY & THERAPEUTICS

Rifampin pharmacokinetics in children, with and without human immunodeficiency virus infection, hospitalized for the management of severe forms of tuberculosis

(2009) Hendrik Simon Schaaf et al.   BMC Medicine

Isoniazid, Rifampin, Ethambutol, and Pyrazinamide Pharmacokinetics and Treatment Outcomes among a Predominantly HIV‐Infected Cohort of Adults with Tuberculosis from Botswana

(2009) Sekai Chideya et al.   CLINICAL INFECTIOUS DISEASES

Tuberculosis pharmacotherapy: strategies to optimize patient care

(2009) Carole D Mitnick et al.   EXPERT OPINION ON PHARMACOTHERAPY

Evaluation of wild-type MIC distributions as a tool for determination of clinical breakpoints for Mycobacterium tuberculosis

(2009) T. Schon et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Therapeutic Drug Monitoring of Antimycobacterial Drugs in Patients with Both Tuberculosis and Advanced Human Immunodeficiency Virus Infection

(2009) David P Holland et al.   PHARMACOTHERAPY

Pharmacokinetics and pharmacodynamics in the development of anti-tuberculosis drugs

(2008) G.R. Davies et al.   TUBERCULOSIS